sale of pharmaceuticals
New challenges and barriers to conventional sale of pharmaceuticals. Key
opinion leader communication. Key opinion leader identification. Stakeholder
specific attitudes. History and rationale. New opportunities for Medical
liasons and KAM's. How to ballance "services", "branding"
and medical science.
Based Medicine and Quality Assessment of clinical science
History and rationale. Critical assessment of literature. Evidence ranking.
Pro’s, con’s and limitations. National variations and cross
border impact. Stakeholder specific attitudes
to Health Technology Assessment and the new medical decision paradigms
New public management and the story of HTA. International HTA-regulations
and bodies. Practical use of HTA in medical decision making. International
and Scandinavian links ot HTA institutions and reports.The concept of “mini-HTA”.
Introduction to Health Economy
Health Economic methods and concepts. Examples. Link to Health Economic
of the Danish Health Care System relevant
to pharmaceutical companies
Governmental bodies and institutions and their role in reimbursement and
market regulation. Regionalisation of decisions. Key opinion leader identification.
Regulatory framework for hospital pharmaceuticals. Health political practice
and financial key-figures.
infrastructure needs in pharmaceutical companies
The new decision paradigms require a more proactive scientific market intelligence,
and delegation of gatekeeper responsibility, together with regular scientific
literature searches and extraction of important market intelligence. Practical
and organisational tools are presented to establish the necessary infrastructure
to comply with these needs to ensure maximal competitive edge.